Dec. 7, 2018 -- Drugmaker Mylan Pharmaceuticals this week announced it has expanded its previous recall of valsartan-based blood pressure medication to include all existing lots of the drug that have not expired.
The expansion includes an additional 104 lots:
26 lots of Amlodipine and Valsartan Tablets, in 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg, and 10 mg/320 mg strengths.
51 lots of Valsartan Tablets in 40 mg, 80 mg, 160 mg, and 320 mg strengths.
27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg strengths).
The drugs were recalled because of trace amounts of an impurity, N-nitrosodiethylamine, or NDEA, which may cause cancer in humans, according to the International Agency for Research on Cancer.
You can find a comprehensive list of all recalled valsartan products here.